LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, ...

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s ...

The EU development comes shortly after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of Leqembi in the US, after a biweekly IV initial induction course ...

Future of Healthcategory· January 27, 2025 US FDA OKs monthly maintenance dosing for Eisai ... Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

A second, somewhat less controversial, anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi ... Recently, a maintenance dosing regimen was approved for lecanemab: after ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...